Hormone sensitive malignancy status

This code indicates that a patient has a malignancy whose growth is influenced by hormones. This sensitivity means that the cancer cells possess receptors that bind to specific hormones, which can either stimulate or inhibit their proliferation. It is a crucial characteristic for determining appropriate treatment strategies.

Use this code when a patient's cancer has been pathologically confirmed or clinically determined to be hormone-sensitive. This is commonly seen in breast cancer (estrogen receptor-positive, progesterone receptor-positive) and prostate cancer (androgen-sensitive). It should be documented as an additional diagnosis to the specific malignancy code.

• Always code the specific malignancy first, then Z19.1 as a secondary diagnosis.
• Ensure documentation clearly states the hormone sensitivity, often through receptor status (e.g., ER+, PR+, AR+).
• Do not use this code for malignancies that are hormone-dependent but not considered "sensitive" in the context of targeted therapy.